OR WAIT null SECS
Mark Barakat, MD
Director of Retinal Research Institute
Retinal Consultants of Arizona
Phoenix, AZ
May 14, 2025
Video
A post-hoc analysis has indicated that aflibercept 8 mg has the potential to shorten or lengthen intervals between treatment in patients with DME.
September 22, 2023
Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.
Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).